A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia

Pediatric Infectious Disease Journal

Volumn 31, Issue 4, 2012, Pages 353-359

  Manji, Arif ^a   Lehrnbecher, Thomas ^b   Dupuis, L Lee ^a,c   Beyene, Joseph ^a,c,d   Sung, Lillian ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

cancer; children; fever; meta analysis; neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CEFEPIME; CEFOZOPRAN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTEREMIA; DOSAGE SCHEDULE COMPARISON; DRUG TREATMENT FAILURE; FEVER; HUMAN; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEVER OF UNKNOWN ORIGIN; HOSPITALS, PEDIATRIC; HUMANS; NEUTROPENIA; PENICILLINS; TREATMENT OUTCOME;

EID: 84858793030     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318242590e     Document Type: Article

References (60)

1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
2. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061-1065.
3. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323-1332.
4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.
5. Chamberlain JD, Smibert E, Skeen J, et al. Prospective audit of treatment of paediatric febrile neutropenia in Australasia. J Paediatr Child Health. 2005;41:598-603. (Pubitemid 43961166)
6. Boragina M, Patel H, Reiter S, et al. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey. Pediatr Blood Cancer. 2007;48:521-526. (Pubitemid 46496346)
7. Phillips B, Selwood K, Lane SM, et al. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group Centres. Arch Dis Child. 2007;92:495-498. (Pubitemid 46867264)
8. Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25:469-473. (Pubitemid 40732600)
9. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344-349. (Pubitemid 351289042)
10. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
11. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144:427-437. (Pubitemid 46768164)
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
13. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177-186. (Pubitemid 43361800)
14. Petrilli AS, Cypriano M, Dantas LS, et al. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma. Braz J Infect Dis. 2003;7:111-120.
15. Uygun V, Karasu GT, Ogunc D, et al. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. Pediatr Blood Cancer. 2009;53:610-614.
16. Vural S, Erdem E, Gulec SG, et al. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int. 2010;52:262-267.
17. Aksoylar S, Cetingul N, Kantar M, et al. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004;21:115-123. (Pubitemid 38313727)
18. Bolton-Maggs PH, van Saene HK, McDowell HP, et al. Clinical evaluation of ticarcillin, with clavulanic acid, and gentamicin in the treatment of febrile episodes in neutropenic children. J Antimicrob Chemother. 1991;27:669-676.
19. Duzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr. 2001;43:105-109. (Pubitemid 32537265)
20. El Haddad AM. Comparison of cefoperazone-sulbactam versus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. Curr Ther Res Clin Exp. 1995;56:1094-1099.
21. Fleischhack G, Schmidt-Niemann M, Wulff B, et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer. 2001;9:372-379. (Pubitemid 32666889)
22. Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841-853. (Pubitemid 32519833)
23. Gonzalez M, Clavell LA. Piperacillin and gentamicin as non toxic empirical therapy in pediatric patients with fever and neutropenia. P R Health Sci J. 1987;6:13-15.
24. Hamidah A, Rizal AM, Nordiah AJ, et al. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J. 2008;49:26-30. (Pubitemid 351239867)
25. Hemsworth S, Nunn AJ, Selwood K, et al. Once-daily netilmicin for neutropenic pyrexia in paediatric oncology. Acta Paediatr. 2005;94:268-274.
26. Heney D, Lewis IJ, Ghoneim AT, et al. Aztreonam therapy in children with febrile neutropenia: a randomized trial of aztreonam plus flucloxacillin versus piperacillin plus gentamicin. J Antimicrob Chemother. 1991;28:117-129.
27. Miranda-Novales MG, Belmont-Martinez L, Villasis-Keever MA, et al. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure. Arch Med Res. 1998;29:331-335. (Pubitemid 29004967)
28. Morgan G, Duerden BI, Lilleyman JS. Ceftazidime as a single agent in the management of children with fever and neutropenia. J Antimicrob Chemother. 1983;12(suppl A):347-351. (Pubitemid 13001010)
29. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med. 1988;319:1053-1058.
30. Smith L, Will AM, Williams RF, et al. Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect. 1990;20:201-206. (Pubitemid 20184393)
31. Zulfikar B, Devecioglu O, Anak S, et al. The efficacy of mezlocillin-amikacin combination in febrile neutropenic children with oncologic disease. J Chemother. 1991;3:250-254.
32. Yildirim I, Aytac S, Ceyhan M, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol. 2008;25:291-299. (Pubitemid 351877035)
33. Ariffin H, Ai CL, Lee CL, et al. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health. 2006;42:781-784. (Pubitemid 44690824)
34. Cagol AR, Castro Junior CG, Martins MC, et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J). 2009;85:531-535.
35. Chuang YY, Hung IJ, Yang CP, et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J. 2002;21:203-209.
36. Corapcioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005;22:59-70. (Pubitemid 40054023)
37. Granowetter L, Wells H, Lange BJ. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient. Pediatr Infect Dis J. 1988;7:165-170. (Pubitemid 18086610)
38. Jacobs RF, Vats TS, Pappa KA, et al. Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children. Infection. 1993;21:223-228. (Pubitemid 23252101)
39. Kebudi R, Gorgun O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001;36:434-441. (Pubitemid 32240457)
40. Kutluk T, Kurne O, Akyuz C, et al. Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer. 2004;42:284-286. (Pubitemid 38235082)
41. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126-134. (Pubitemid 29293385)
42. Mustafa MM, Carlson L, Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2001;20:362-369. (Pubitemid 32240289)
43. Oguz A, Karadeniz C, Citak EC, et al. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatr Hematol Oncol. 2006;23:245-253. (Pubitemid 43361806)
44. Pereira CA, Petrilli AS, Carlesse FA, et al. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison. J Microbiol Immunol Infect. 2009;42:141-147.
45. Sato T, Kobayashi R, Yasuda K, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer. 2008;51:774-777.
46. Ariffin H, Arasu A, Mahfuzah M, et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Paediatr Child Health. 2001;37:38-43. (Pubitemid 32163511)
47. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J. 1997;16:346-353. (Pubitemid 27173246)
48. Chastagner P, Plouvier E, Eyer D, et al. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer. Med Pediatr Oncol. 2000;34:306-308. (Pubitemid 30176620)
49. Hamidah A, Lim YS, Zulkifli SZ, et al. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J. 2007;48:615-619. (Pubitemid 351396789)
50. Hung KC, Chiu HH, Tseng YC, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect. 2003;36:254-259.
51. Laoprasopwattana K, Pruekprasert P, Laosombat V, et al. Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides. Pediatr Hematol Oncol. 2007;24:595-606. (Pubitemid 350301884)
52. Maltezou HC, Baka M, Gombakis N, et al. Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies. Int J Antimicrob Agents. 2001;18:383-386. (Pubitemid 33016354)
53. Viscoli C, Moroni C, Boni L, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis. 1991;13:397-404.
54. Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010:CD005197.
55. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338-348. (Pubitemid 46591956)
56. Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51:381-389.
57. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002;2:231-242. (Pubitemid 34464753)
58. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111.
59. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051. (Pubitemid 30644129)
60. Moher D, Pham B, Klassen TP, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol. 2000;53:964-972.